$82.04
+0.74
(+0.91%)▲
1.37%
Downside
Day's Volatility :2.05%
Upside
0.68%
60.98%
Downside
52 Weeks Volatility :65.82%
Upside
12.4%
Period | Radnet Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 26.87% | -6.9% | 0.0% |
6 Months | 40.0% | -1.7% | 0.0% |
1 Year | 153.35% | 10.4% | 0.0% |
3 Years | 177.85% | 8.8% | -24.1% |
Market Capitalization | 6.1B |
Book Value | $12.10 |
Earnings Per Share (EPS) | -0.07 |
PEG Ratio | 2.32 |
Wall Street Target Price | 86.833 |
Profit Margin | -0.25% |
Operating Margin TTM | 7.71% |
Return On Assets TTM | 2.39% |
Return On Equity TTM | 3.2% |
Revenue TTM | 1.8B |
Revenue Per Share TTM | 24.82 |
Quarterly Revenue Growth YOY | 14.7% |
Gross Profit TTM | 288.8M |
EBITDA | 248.4M |
Diluted Eps TTM | -0.07 |
Quarterly Earnings Growth YOY | -0.84 |
EPS Estimate Current Year | 0.67 |
EPS Estimate Next Year | 0.87 |
EPS Estimate Current Quarter | 0.15 |
EPS Estimate Next Quarter | 0.21 |
What analysts predicted
Upside of 5.84%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 975.1M | ↑ 5.74% |
Net Income | 32.2M | ↑ 60735.85% |
Net Profit Margin | 3.31% | ↑ 3.3% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.2B | ↑ 18.36% |
Net Income | 23.4M | ↓ 27.3% |
Net Profit Margin | 2.03% | ↓ 1.28% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↓ 7.13% |
Net Income | -1.7M | ↓ 107.46% |
Net Profit Margin | -0.16% | ↓ 2.19% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.3B | ↑ 22.69% |
Net Income | 44.3M | ↓ 2633.96% |
Net Profit Margin | 3.37% | ↑ 3.53% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.4B | ↑ 8.74% |
Net Income | 33.6M | ↓ 24.17% |
Net Profit Margin | 2.35% | ↓ 1.02% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.6B | ↑ 13.05% |
Net Income | 3.0M | ↓ 90.94% |
Net Profit Margin | 0.19% | ↓ 2.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 403.7M | ↑ 3.37% |
Net Income | 8.4M | ↓ 158.59% |
Net Profit Margin | 2.07% | ↑ 5.73% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 402.0M | ↓ 0.43% |
Net Income | 17.5M | ↑ 109.58% |
Net Profit Margin | 4.36% | ↑ 2.29% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 420.4M | ↑ 4.58% |
Net Income | -1.9M | ↓ 110.6% |
Net Profit Margin | -0.44% | ↓ 4.8% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 431.7M | ↑ 2.69% |
Net Income | -2.8M | ↑ 49.41% |
Net Profit Margin | -0.64% | ↓ 0.2% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 459.7M | ↑ 6.49% |
Net Income | -3.0M | ↑ 7.3% |
Net Profit Margin | -0.65% | ↓ 0.01% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 461.1M | ↑ 0.31% |
Net Income | 20.9M | ↓ 801.74% |
Net Profit Margin | 4.54% | ↑ 5.19% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 27.66% |
Total Liabilities | 909.1M | ↑ 13.77% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 48.34% |
Total Liabilities | 1.4B | ↑ 55.37% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 8.57% |
Total Liabilities | 1.5B | ↑ 8.2% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.1B | ↑ 15.21% |
Total Liabilities | 1.7B | ↑ 12.04% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↑ 18.24% |
Total Liabilities | 1.9B | ↑ 13.44% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.7B | ↑ 10.54% |
Total Liabilities | 1.9B | ↓ 3.36% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↑ 12.06% |
Total Liabilities | 1.9B | ↑ 1.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↓ 0.64% |
Total Liabilities | 1.9B | ↓ 2.7% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.9B | ↑ 7.39% |
Total Liabilities | 2.1B | ↑ 9.59% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.0B | ↑ 2.87% |
Total Liabilities | 1.9B | ↓ 8.73% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.2B | ↑ 8.75% |
Total Liabilities | 2.1B | ↑ 12.91% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 3.3B | ↑ 1.42% |
Total Liabilities | 2.2B | ↑ 0.9% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 116.8M | ↓ 17.31% |
Investing Cash Flow | -146.7M | ↑ 85.01% |
Financing Cash Flow | -10.9M | ↓ 66.29% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 104.3M | ↓ 10.65% |
Investing Cash Flow | -99.5M | ↓ 32.22% |
Financing Cash Flow | 25.0M | ↓ 329.56% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 233.8M | ↑ 124.07% |
Investing Cash Flow | -126.2M | ↑ 26.92% |
Financing Cash Flow | -45.6M | ↓ 282.6% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 149.5M | ↓ 36.05% |
Investing Cash Flow | -221.5M | ↑ 75.46% |
Financing Cash Flow | 104.7M | ↓ 329.74% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 146.4M | ↓ 2.06% |
Investing Cash Flow | -246.9M | ↑ 11.48% |
Financing Cash Flow | 93.6M | ↓ 10.53% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 68.1M | ↑ 108.72% |
Investing Cash Flow | -40.4M | ↓ 38.44% |
Financing Cash Flow | 238.1M | ↓ 6331.95% |
Sell
Neutral
Buy
Radnet Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Radnet Inc | 20.28% | 40.0% | 153.35% | 177.85% | 341.61% |
Idexx Laboratories, Inc. | -9.3% | -19.19% | -12.5% | -34.05% | 62.85% |
Agilent Technologies Inc. | -1.05% | -13.61% | 6.51% | -18.87% | 66.91% |
Thermo Fisher Scientific, Inc. | -11.99% | -12.64% | 5.86% | -18.59% | 67.69% |
Danaher Corp. | -10.04% | -12.03% | 6.21% | -25.08% | 64.0% |
Iqvia Holdings Inc. | -13.45% | -12.58% | -5.69% | -26.13% | 37.47% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Radnet Inc | 442.11 | NA | 2.32 | 0.67 | 0.03 | 0.02 | NA | 12.1 |
Idexx Laboratories, Inc. | 40.48 | 40.48 | 4.41 | 10.73 | 0.59 | 0.23 | NA | 19.72 |
Agilent Technologies Inc. | 27.46 | 27.46 | 2.77 | 5.24 | 0.25 | 0.08 | 0.01 | 20.53 |
Thermo Fisher Scientific, Inc. | 32.15 | 32.15 | 1.95 | 21.69 | 0.13 | 0.05 | 0.0 | 128.08 |
Danaher Corp. | 44.06 | 44.06 | 2.74 | 7.5 | 0.08 | 0.04 | 0.0 | 71.03 |
Iqvia Holdings Inc. | 25.93 | 25.93 | 1.01 | 11.14 | 0.22 | 0.05 | NA | 38.37 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Radnet Inc | Buy | $6.1B | 341.61% | 442.11 | -0.25% |
Idexx Laboratories, Inc. | Buy | $34.3B | 62.85% | 40.48 | 22.53% |
Agilent Technologies Inc. | Buy | $37.9B | 66.91% | 27.46 | 21.75% |
Thermo Fisher Scientific, Inc. | Buy | $196.2B | 67.69% | 32.15 | 14.48% |
Danaher Corp. | Buy | $168.4B | 64.0% | 44.06 | 16.39% |
Iqvia Holdings Inc. | Buy | $35.9B | 37.47% | 25.93 | 9.17% |
Insights on Radnet Inc
Revenue is up for the last 5 quarters, 401.96M → 461.14M (in $), with an average increase of 3.4% per quarter
Netprofit is up for the last 2 quarters, -2.98M → 20.92M (in $), with an average increase of 114.3% per quarter
BlackRock Inc
Vanguard Group Inc
Beck, Mack & Oliver LLC
State Street Corp
RTW INVESTMENTS, LLC
Dimensional Fund Advisors, Inc.
radnet, inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the united states based on the number of locations and annual imaging revenue. radnet has a network of 340+ owned and/or operated outpatient imaging centers. radnet's core markets include california, delaware, maryland, new jersey, and new york. together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, radnet has a total of approximately 7,300 employees.
Organization | Radnet Inc |
Employees | 10000 |
CEO | Dr. Howard G. Berger M.D. |
Industry | Health Services |
Cleanspark Inc
$82.04
+0.91%
Vaneck Vectors Fallen Angel Hiyld Bd Etf
$82.04
+0.91%
Borgwarner Inc.
$82.04
+0.91%
Central Garden & Pet Co A Shares
$82.04
+0.91%
Esab Corp
$82.04
+0.91%
Sasol Ltd.
$82.04
+0.91%
Ishares Msci Eafe Min Vol Factor Etf
$82.04
+0.91%
Vanguard Ultra Short Bond Et
$82.04
+0.91%
Hutchison China Meditech Limited
$82.04
+0.91%